LENSAR, Inc. (LNSR) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
5.96$'dan işlem gören LENSAR, Inc. (LNSR), $71.19M değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 57/100 puan alıyor.
Son analiz: 8 Şub 2026LENSAR, Inc. (LNSR) Sağlık ve Boru Hattı Genel Bakışı
LENSAR, Inc. revolutionizes cataract surgery with its advanced femtosecond laser system, offering surgeons unparalleled precision and improved patient outcomes. Targeting a multi-billion dollar market, LENSAR's innovative technology and strategic focus on astigmatism management position it for significant growth and market share gains in the medical device industry.
Yatırım Tezi
LENSAR, Inc. presents a notable research candidate driven by its innovative LENSAR Laser System and its potential to capture a larger share of the growing cataract surgery market. With a market capitalization of $0.14 billion, LENSAR offers significant upside potential as it expands its installed base and increases utilization rates. The company's focus on astigmatism management provides a key differentiator, addressing a significant unmet need in refractive cataract surgery. Key value drivers include increasing adoption of femtosecond laser-assisted cataract surgery (FLACS), expanding applications for the LENSAR Laser System, and strategic partnerships to broaden market reach. Upcoming catalysts include potential regulatory approvals for new features and enhancements, as well as positive clinical data demonstrating improved patient outcomes. The company's gross margin of 45.8% indicates strong pricing power and potential for further margin expansion as the business scales.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.14 billion indicates substantial growth potential.
- Gross margin of 45.8% reflects strong pricing power in the medical device market.
- Beta of 0.65 suggests lower volatility compared to the overall market.
- Focus on astigmatism management provides a key differentiator in the cataract surgery market.
- LENSAR Laser System incorporates proprietary technologies designed to improve surgical outcomes.
Rakipler & Benzerleri
Güçlü Yönler
- Proprietary LENSAR Laser System with advanced features.
- Focus on astigmatism management.
- Established presence in the femtosecond laser-assisted cataract surgery (FLACS) market.
- Experienced management team with expertise in medical devices.
Zayıflıklar
- Relatively small market capitalization compared to larger competitors.
- Negative profit margin.
- Dependence on a single product line.
- Limited financial resources for marketing and sales.
Katalizörler
- Upcoming: Potential regulatory approvals for new features and enhancements to the LENSAR Laser System.
- Ongoing: Increasing adoption of femtosecond laser-assisted cataract surgery (FLACS).
- Ongoing: Strategic partnerships to expand market reach.
- Upcoming: Positive clinical data demonstrating improved patient outcomes.
- Ongoing: Expansion into new international markets.
Riskler
- Potential: Competition from larger medical device companies with greater resources.
- Potential: Technological advancements by competitors that could render the LENSAR Laser System obsolete.
- Potential: Changes in reimbursement policies that could reduce the profitability of FLACS.
- Potential: Economic downturn affecting hospital capital spending and demand for medical devices.
- Ongoing: Reliance on a single product line makes the company vulnerable to market shifts.
Büyüme Fırsatları
- Expanding the Installed Base: LENSAR has the opportunity to increase its market share by expanding its installed base of LENSAR Laser Systems. This can be achieved through targeted marketing efforts, strategic partnerships with ophthalmic surgeons and hospitals, and competitive pricing strategies. The global market for cataract surgery equipment is projected to reach billions of dollars, providing a substantial opportunity for LENSAR to grow its revenue and profitability. Timeline: Ongoing.
- Increasing Utilization Rates: Driving higher utilization rates of existing LENSAR Laser Systems is another key growth driver. This involves providing comprehensive training and support to surgeons, promoting the benefits of FLACS to patients, and developing new applications for the LENSAR Laser System. By maximizing the utilization of its installed base, LENSAR can generate recurring revenue and improve its financial performance. Timeline: Ongoing.
- Developing New Applications: LENSAR can further expand its market opportunity by developing new applications for its laser technology. This could include expanding into other refractive procedures, such as corneal refractive surgery, or developing new features and enhancements for the LENSAR Laser System. By diversifying its product offerings, LENSAR can attract new customers and increase its revenue streams. Timeline: 2-3 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other companies in the ophthalmic industry can accelerate LENSAR's growth. This could involve partnering with companies that offer complementary products or services, such as intraocular lenses (IOLs) or surgical instruments. By leveraging the expertise and resources of its partners, LENSAR can expand its market reach and improve its competitive position. Timeline: Ongoing.
- International Expansion: LENSAR has the opportunity to expand its geographic reach by entering new international markets. This could involve targeting countries with aging populations and growing demand for advanced cataract surgery technologies. By expanding its international presence, LENSAR can diversify its revenue streams and reduce its reliance on the U.S. market. Timeline: 3-5 years.
Fırsatlar
- Expanding the installed base of LENSAR Laser Systems.
- Increasing utilization rates of existing systems.
- Developing new applications for the laser technology.
- Entering new international markets.
Tehditler
- Competition from larger medical device companies.
- Technological advancements by competitors.
- Changes in reimbursement policies.
- Economic downturn affecting hospital capital spending.
Rekabet Avantajları
- Proprietary laser technology with patents protecting key innovations.
- Established brand reputation for precision and reliability.
- Strong relationships with ophthalmic surgeons and hospitals.
- High switching costs due to training and integration requirements.
LNSR Hakkında
LENSAR, Inc., founded in 2004 and headquartered in Orlando, Florida, is a commercial-stage medical device company dedicated to transforming cataract surgery through advanced laser technology. The company designs, develops, and markets the LENSAR Laser System, a femtosecond laser platform used for cataract treatment and the management of pre-existing or surgically induced corneal astigmatism. LENSAR's core innovation lies in its proprietary technologies that provide surgeons with enhanced imaging, procedure planning, design capabilities, and precision, ultimately leading to improved visual outcomes, greater efficiency, and enhanced reproducibility. The LENSAR Laser System integrates advanced 3D modeling and augmented reality to assist surgeons in creating personalized treatment plans. This technology allows for precise corneal and lens incisions, as well as accurate fragmentation of the cataract, reducing the need for manual techniques and minimizing potential complications. By focusing on precision and automation, LENSAR aims to improve the overall surgical experience for both surgeons and patients. The company's commitment to innovation and clinical excellence positions it as a key player in the evolving landscape of refractive cataract surgery.
Ne Yaparlar
- Designs and develops femtosecond laser systems for cataract surgery.
- Markets the LENSAR Laser System to ophthalmic surgeons and hospitals.
- Provides advanced imaging and procedure planning capabilities.
- Offers precision laser technology for corneal and lens incisions.
- Facilitates the management of pre-existing or surgically induced astigmatism.
- Aims to improve visual outcomes and surgical efficiency.
- Provides training and support to surgeons using the LENSAR Laser System.
İş Modeli
- Sells LENSAR Laser Systems to hospitals and surgical centers.
- Generates revenue from service contracts and maintenance agreements.
- Offers training and support services to surgeons.
- Potential revenue from disposables used during procedures.
Sektör Bağlamı
The medical device industry is characterized by continuous innovation and increasing demand for minimally invasive surgical procedures. The cataract surgery market is a significant segment, driven by an aging population and advancements in surgical techniques. LENSAR operates within the femtosecond laser-assisted cataract surgery (FLACS) sub-segment, which is experiencing rapid growth due to its precision and improved patient outcomes. Competitors include ARAY, ANIK, AVR, CRBP and CRDF, each vying for market share with their respective laser systems and technologies. LENSAR's focus on astigmatism management and its proprietary technologies position it favorably within this competitive landscape.
Kilit Müşteriler
- Ophthalmic surgeons specializing in cataract surgery.
- Hospitals and surgical centers offering cataract surgery services.
- Patients seeking advanced cataract treatment options.
Finansallar
Grafik & Bilgi
LENSAR, Inc. (LNSR) hisse senedi fiyatı: $5.96 (-0.31, -4.50%)
Son Haberler
-
Earnings Scheduled For March 31, 2026
benzinga · 31 Mar 2026
-
This Block Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
benzinga · 18 Mar 2026
-
Sector Update: Health Care Stocks Fall Late Afternoon
MT Newswires · 17 Mar 2026
-
Sector Update: Health Care Stocks Decline Tuesday Afternoon
MT Newswires · 17 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
LNSR için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $10.00
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, LNSR'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
Earnings Scheduled For March 31, 2026
This Block Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
Sector Update: Health Care Stocks Fall Late Afternoon
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Yatırımcılar LENSAR, Inc. (LNSR) Hakkında Ne Soruyor
LNSR için değerlendirilmesi gereken temel faktörler nelerdir?
LENSAR, Inc. (LNSR) şu anda yapay zeka skoru 57/100, orta puanı gösteriyor. Analist hedefi $10.00 ($5.96'dan +68%). Temel güçlü yan: Proprietary LENSAR Laser System with advanced features.. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device companies with greater resources.. Bu bir finansal tavsiye değildir.
LNSR MoonshotScore'u nedir?
LNSR şu anda MoonshotScore'da 57/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
LNSR verileri ne sıklıkla güncellenir?
LNSR fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler LNSR hakkında ne diyor?
Analistler, LNSR için $10.00 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($5.96) yukarı yönlü %68 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
LNSR'a yatırım yapmanın riskleri nelerdir?
LNSR için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device companies with greater resources.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
LNSR'ın P/E oranı nedir?
LNSR için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için LNSR'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
LNSR aşırı değerli mi, yoksa düşük değerli mi?
LENSAR, Inc. (LNSR)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Analist hedefi $10.00 (mevcut fiyattan +68%), analistlerin yukarı yönlü potansiyel gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
LNSR'ın temettü verimi nedir?
LENSAR, Inc. (LNSR) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Stock data pending update.
- Financial data based on available information and may be subject to change.